ALK and non-small cell lung carcinoma: Crizotinib is used as one of the first targeted therapies for ALK-positive NSCLC (first-generation therapy), which shows a longer progression-free survival (PFS) when compared to chemotherapy, with a PFS of 10.9 months for crizotinib compared to 7.0 months for chemotherapy.